鼻内给予乙酰胆碱酯酶抑制剂。
Intranasal administration of acetylcholinesterase inhibitors.
作者信息
Costantino Henry R, Leonard Alexis Kays, Brandt Gordon, Johnson Paul H, Quay Steven C
机构信息
Nastech Pharmaceutical Company Inc, 3830 Monte Villa Parkway, Bothell, WA 98021, USA.
出版信息
BMC Neurosci. 2008 Dec 10;9 Suppl 3(Suppl 3):S6. doi: 10.1186/1471-2202-9-S3-S6.
Abstract
This short review outlines the rationale, challenges, and opportunities for intranasal acetylcholinesterases, in particular galantamine. An in vitro screening model facilitated the development of a therapeutically viable formulation. In vivo testing confirmed achievement of therapeutically relevant drug levels that matched or exceeded those for oral dosing, with a dramatic reduction in undesired emetic responses. Intranasal drug delivery is an effective option for the treatment of Alzheimer's disease and other central nervous system disorders.
摘要
这篇简短的综述概述了鼻内给予乙酰胆碱酯酶，尤其是加兰他敏的基本原理、挑战和机遇。体外筛选模型推动了一种具有治疗可行性的制剂的研发。体内试验证实达到了与口服给药相当或更高的治疗相关药物水平，且意外的催吐反应显著减少。鼻内给药是治疗阿尔茨海默病和其他中枢神经系统疾病的有效选择。
相似文献
1
Intranasal administration of acetylcholinesterase inhibitors.
BMC Neurosci. 2008 Dec 10;9 Suppl 3(Suppl 3):S6. doi: 10.1186/1471-2202-9-S3-S6.
2
In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo.
Int J Pharm. 2007 Apr 20;335(1-2):138-146. doi: 10.1016/j.ijpharm.2006.11.013. Epub 2006 Nov 16.
3
Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice.
Curr Drug Deliv. 2019;16(1):51-58. doi: 10.2174/1567201815666181004094707.
4
Brain targeting efficacy of novel drug delivery system in the treatment of Alzheimer's disease.
Eur Rev Med Pharmacol Sci. 2024 Jul;28(13):3892-3904. doi: 10.26355/eurrev_202407_36521.
5
Development of a novel high-concentration galantamine formulation suitable for intranasal delivery.
J Pharm Sci. 2005 Aug;94(8):1736-46. doi: 10.1002/jps.20389.
6
Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
J Control Release. 2018 Jul 10;281:139-177. doi: 10.1016/j.jconrel.2018.05.011. Epub 2018 May 24.
7
Formulation and evaluation of galantamine gel as drug reservoir in transdermal patch delivery system.
ScientificWorldJournal. 2015;2015:495271. doi: 10.1155/2015/495271. Epub 2015 Feb 26.
8
Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting.
Pharm Res. 2018 Jan 2;35(1):8. doi: 10.1007/s11095-017-2279-z.
9
[Galantamine, an acetylcholinesterase inhibitor with various actions].
Med Monatsschr Pharm. 2004 Jul;27(7):223-7.
10
Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes.
Environ Toxicol Pharmacol. 2012 Sep;34(2):272-279. doi: 10.1016/j.etap.2012.04.012. Epub 2012 May 3.
引用本文的文献
1
Natural products as sources of acetylcholinesterase inhibitors: Synthesis, biological activities, and molecular docking studies of osthole-based ester derivatives.
Front Plant Sci. 2022 Nov 18;13:1054650. doi: 10.3389/fpls.2022.1054650. eCollection 2022.
2
Natural Peptides in Drug Discovery Targeting Acetylcholinesterase.
Molecules. 2018 Sep 13;23(9):2344. doi: 10.3390/molecules23092344.
3
Intranasal Cotinine Plus Krill Oil Facilitates Fear Extinction, Decreases Depressive-Like Behavior, and Increases Hippocampal Calcineurin A Levels in Mice.
Mol Neurobiol. 2018 Oct;55(10):7949-7960. doi: 10.1007/s12035-018-0916-0. Epub 2018 Feb 27.
4
Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice.
J Neurol Neurosurg. 2015;2(1).
5
Acetylcholinesterase inhibitor modifications: a promising strategy to delay the progression of Alzheimer's disease.
Neural Regen Res. 2015 Jan;10(1):43-5. doi: 10.4103/1673-5374.150648.
本文引用的文献
1
Intranasal delivery: physicochemical and therapeutic aspects.
Int J Pharm. 2007 Jun 7;337(1-2):1-24. doi: 10.1016/j.ijpharm.2007.03.025. Epub 2007 Mar 25.
2
Alzheimer's disease a century later.
J Clin Psychiatry. 2006 Nov;67(11):1784-800. doi: 10.4088/jcp.v67n1118.
3
In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo.
Int J Pharm. 2007 Apr 20;335(1-2):138-146. doi: 10.1016/j.ijpharm.2006.11.013. Epub 2006 Nov 16.
4
Realistic expectations for treatment success in Alzheimer's disease.
J Nutr Health Aging. 2006 Sep-Oct;10(5):417-29.
5
Therapeutic approaches to Alzheimer's disease.
Brain. 2006 Nov;129(Pt 11):2840-55. doi: 10.1093/brain/awl280. Epub 2006 Oct 3.
6
Direct nose-to-brain transfer of morphine after nasal administration to rats.
Pharm Res. 2006 Mar;23(3):565-72. doi: 10.1007/s11095-006-9534-z. Epub 2006 Feb 25.
7
Advances in nasal drug delivery through tight junction technology.
Expert Opin Drug Deliv. 2005 Mar;2(2):281-98. doi: 10.1517/17425247.2.2.281.
8
Study on brain targeting of raltitrexed following intranasal administration in rats.
Cancer Chemother Pharmacol. 2006 Jan;57(1):97-104. doi: 10.1007/s00280-005-0018-3. Epub 2005 Nov 5.
9
Development of a novel high-concentration galantamine formulation suitable for intranasal delivery.
J Pharm Sci. 2005 Aug;94(8):1736-46. doi: 10.1002/jps.20389.
10
Cholinesterases: roles in the brain during health and disease.
Curr Alzheimer Res. 2005 Jul;2(3):307-18. doi: 10.2174/1567205054367838.
Zotero 插件